Klein Lawrence Otto 4
4 · CRISPR Therapeutics AG · Filed Mar 14, 2022
Insider Transaction Report
Form 4
Klein Lawrence Otto
Chief Business Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2022-03-10−4,584→ 4,583 total→ Common Shares (4,584 underlying) - Exercise/Conversion
Common Shares
2022-03-11+3,000→ 28,026 total - Tax Payment
Common Shares
2022-03-14$61.08/sh−1,229$75,067→ 26,797 total - Exercise/Conversion
Restricted Stock Units
2022-03-11−3,000→ 9,000 total→ Common Shares (3,000 underlying) - Exercise/Conversion
Common Shares
2022-03-10+4,584→ 26,909 total - Tax Payment
Common Shares
2022-03-11$62.56/sh−1,883$117,800→ 25,026 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F3]This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.
- [F4]This restricted stock unit award was granted on March 11, 2021 with respect to 12,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024 and (iv) one quarter of the shares vesting on March 11, 2025.